Thyrocare Technologies Limited has informed the Exchange that the Board of Directors at its meeting held on October 14, 2025, has considered, approved, and recommended to the shareholders the issuance of bonus shares in the ratio of 2:1, i.e., 2 new equity shares for every 1 existing equity share, subject to the approval of the shareholders.
THYROCARE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Thyrocare Technologies' Board of Directors, at a meeting held on October 14, 2025, has approved and recommended the issuance of bonus shares in the ratio of 2:1 — meaning 2 new equity shares for every 1 existing share held. The bonus issue is subject to shareholder approval. The record date for determining eligible shareholders will be announced later. This is a significant capital action that will increase the total number of outstanding shares but does not change the overall value of a shareholder's holding.
Shareholders will receive 2 additional shares for each share they own, effectively tripling their share count. The share price is expected to adjust downward proportionally post the ex-date, so total investment value remains unchanged in the short term, though higher liquidity may attract more retail participation.